Fluciclovine PET/CT in Multiple Myeloma Patients (FLUCIPET)

May 28, 2019 updated by: Mona-Elisabeth Revheim, Oslo University Hospital

PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose

Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

10

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Mona-Elisabeth Revheim, MD, PhD, MHA
  • Phone Number: +4790659373
  • Email: monar@ous-hf.no

Study Locations

  • Norway
      • Oslo, Norway, 0424
        • Recruiting
        • Oslo University Hosptal
        • Principal Investigator:
          • Mona-Elisabeth Revheim, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Multiple myeloma patients

Description

Inclusion Criteria:

  • Multiple myeloma patients suitable for ASCT treatment

Exclusion Criteria:

  • Patients with contraindications to ASCT treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Comparing of image findings at PET
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Oslo University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2019

Primary Completion (Anticipated)

January 31, 2020

Study Completion (Anticipated)

January 31, 2029

Study Registration Dates

First Submitted

May 27, 2019

First Submitted That Met QC Criteria

May 28, 2019

First Posted (Actual)

May 29, 2019

Study Record Updates

Last Update Posted (Actual)

May 30, 2019

Last Update Submitted That Met QC Criteria

May 28, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2018/2212/REK

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myeloma, Multiple

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe